NMOSD

Xencor Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 9, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, FDA, CD3, Cancer, Bangladesh Technical Education Board, CLDN6, Investment, Cell, NIH, Xtend, Malaria, NMOSD, Research, IND, Prostate cancer, European, CD28, Ravulizumab, Patient, ENPP3, Alexion, Immune system, Clinical trial, Ovarian cancer

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.
  • New Chief Financial Officer Appointed: Bart Cornelissen was appointed as Xencor’s senior vice president and chief financial officer.
  • Financial Results for the First Quarter Ended March 31, 2024
    Cash, cash equivalents and marketable debt securities totaled $646.7 million as of March 31, 2024, compared to $697.4 million on December 31, 2023.
  • Revenues for the first quarter ended March 31, 2024 were $12.8 million, compared to $19.0 million for the same period in 2023.

Q1 2024 results

Retrieved on: 
Thursday, April 25, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Annual general meeting, Annual, Osimertinib, LAURA, Dive (Belgian band), Lung cancer, PTEN, NMOSD, CER, FY, Blas, Outline, Budesonide, Total revenue, Growth, AstraZeneca, ASCO, EVH, Acquisition, EPS, PNH, ALPHA, NSCLC, Pharmaceutical industry

The increase in Core EPS was lower than Total Revenue growth principally due to a $241m gain in the prior year period on the disposal of Pulmicort Flexhaler US rights

Key Points: 
  • The increase in Core EPS was lower than Total Revenue growth principally due to a $241m gain in the prior year period on the disposal of Pulmicort Flexhaler US rights
    As announced at the Annual General Meeting on 11 April 2024, the total dividend for FY 2024 will increase by $0.20 per share to $3.10 per share
    "AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter.
  • We are also looking forward to seeing the results of several other important trials throughout the year.
  • If foreign exchange rates for April 2024 to December 2024 were to remain at the average rates seen in March 2024, compared to the performance at CER it is anticipated that FY 2024 Total Revenue would incur a low single-digit adverse impact and Core EPS would incur a mid single-digit adverse impact (previously low single-digit).
  • AstraZeneca will host an Investor Day on 21 May 2024.

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

Good News--MS Drugs Taken While Breastfeeding May Not Affect Child Development

Retrieved on: 
Tuesday, March 5, 2024
NMOSD, Social media, Hellwig, Nervous system, Alzheimer's disease, MD, Ofatumumab, Stroke, German, Pregnancy, Life, Risk, Annual general meeting, Multiple sclerosis, DSM-IV codes, AAN, Health, Migraine, Parkinson's disease, Hypoesthesia, Fatigue, Ruhr University Bochum, Mother, Paresthesia, Infant, Concussion, Spinal cord, Breast milk, Epilepsy, Sclerosis, Disease, Child, Rituximab, Natalizumab, Optic nerve, Brain, Demyelinating disease, Research, Immune system, American Academy, Birth control

MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.

Key Points: 
  • MS is a disease in which the body's immune system attacks myelin, the fatty white substance that insulates and protects the nerves.
  • For the study, researchers used the German MS and Pregnancy Registry to identify 183 infants born to mothers taking monoclonal antibodies while breastfeeding.
  • The first exposures to the medications through breastfeeding ranged from the day a child was born to the ninth month of life.
  • After comparing infants exposed to the medications to infants not exposed, researchers found no differences in their health or development.

Health Canada Approves UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD)

Retrieved on: 
Tuesday, January 16, 2024
Death, Fellow, Patient, Therapy, Ottawa Hospital Research Institute, Multiple sclerosis, Paratriathlon, University, ANVISA, Autoimmune disease, Risk, Food, Disease, Central nervous system, Labour, Ministry of Health, FDA, Pain, Physician, Inflammation, NMOSD, Clinical trial, B cell, Health Canada, Paralysis, Brazilian Health Regulatory Agency, Pharmaceutical industry

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death –

Key Points: 
  • "Just a single NMOSD attack can have a life-altering impact, including pain, debilitation and irreversible vision loss.
  • Health Canada based its approval of UPLIZNA on results from the N-MOmentum pivotal trial ( 2014-000253-36 ), the largest NMOSD clinical trial to date.
  • UPLIZNA demonstrated a significant reduction in the risk of an NMOSD attack with only two infusions per year, following the initial loading doses.
  • "We can now accurately diagnose NMOSD, which is distinctly different from MS and warrants specific treatment.

Aeterna Zentaris Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
MFDS, European Economic Area, Result, AIM, Conversation, Research, Bank statement, Financial condition report, ALS, Neuromyelitis optica spectrum disorder, Marketing, Analysis, EEA, NMOSD, Patient, TSX, General Administration of Press and Publication, Cryptocurrency, Clothing, Rare-earth element, Aeterna

TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the quarter ended September 30, 2023.

Key Points: 
  • - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline programs into 2025
    TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the quarter ended September 30, 2023.
  • Dollars
    The Company had $38.8 million in cash and cash equivalents at September 30, 2023.
  • Our total revenue for the nine-month period ended September 30, 2023, was $4.4 million as compared to $3.2 million for the same period in 2022, representing an increase of $1.2 million.
  • For reference, the Company’s Management's Discussion and Analysis of Financial Condition and Results of Operations for the third quarter 2023, as well as the Company's unaudited consolidated interim financial statements as of September 30, 2023, will be available on the Company's website ( www.zentaris.com ) in the Investors section or at the Company's profile at www.sedarplus.com and www.sec.gov .

ECTRIMS to Host Global Patient-Community Event in Milan, Italy

Retrieved on: 
Tuesday, October 3, 2023
Health, Other Consumer, Consumer, Other Health, Managed Care, Pharmaceutical, Biotechnology, Human, NMOSD, Research, Multiple sclerosis, Person, MS, MOGAD, Allianz, Patient, Treatment, Online shopping

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will host MSMilan Patient Community Day on Saturday 14 October 2023, 15:00–17:00 CEST, at the Allianz MiCo Centre in Milan, Italy.

Key Points: 
  • The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will host MSMilan Patient Community Day on Saturday 14 October 2023, 15:00–17:00 CEST, at the Allianz MiCo Centre in Milan, Italy.
  • “We hope this event empowers those living with this and other related conditions to be better informed about decision making affecting their treatment and care options”.
  • Participation is free of charge, but pre-registration is required at this link ( https://ectrims.eu/msmilan2023-msmilan-patient-community-day/ ) on the ECTRIMS MSMilan 2023 website.
  • The event will be live streamed in English on ECTRIMS website ( https://ectrims.eu/msmilan2023-msmilan-patient-community-day/ ), with translation offered in Italian, German, French, Spanish, and Portuguese.

Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023

Retrieved on: 
Monday, October 2, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Civil service commission, ANVISA, Azathioprine, Multiple sclerosis, Congress, European Commission, Evaluation, CEST, Brazilian Health Regulatory Agency, Regulation of tobacco by the U.S. Food and Drug Administration, Treatment, Food, Pharmaceutical industry, NMOSD, Inebilizumab, Patient

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023, Oct. 11-13.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023, Oct. 11-13.
  • UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the U.S. Food and Drug Administration, the European Commission and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of NMOSD in adults who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+).
  • P015: Association of Cytokine Proteins with Disease Activity in NMOSD Participants Receiving Inebilizumab Treatment (S. Pittock)
    P409: Long-Term Comparative Efficacy of Inebilizumab in the AQP4+ Subpopulation from the N-MOmentum Open-Label Extension Versus Azathioprine and Immunosuppressive Therapies and Versus Placebo in Patients with NMOSD (B. Cree)
    P011: Matching-Adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-Term Effectiveness (F. Paul)
    Horizon will host a symposium Thursday, Oct. 12 from 8:45 to 9:45 a.m. CEST, “Looking for unrecognized disease activity in NMOSD to optimize treatment choice and prevent disability,” chaired by Massimo Filippi, M.D., Ph.D., featuring presentations from Maria Rocca, M.D., Orhan Aktas, M.D.
  • and Jeffrey Bennett, M.D., Ph.D.

Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD

Retrieved on: 
Monday, October 2, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Sclerosis, Abstract, Cerebrospinal fluid, Use, Safety, Pregnancy, COVID-19, Clinical trial, Utility, Woman, PIRA, NMOSD, COMPASS, Biomarker, Multiple sclerosis, Ocrelizumab, MS, MRI, Patient, Phases of clinical research, Infant, Neuromyelitis optica spectrum disorder, Phase, Flour, Pharmaceutical industry, Frankincense, Dietary supplement, Medical imaging

Regular abstracts available from October 01, 2023 at 8:00 CEST.

Key Points: 
  • Regular abstracts available from October 01, 2023 at 8:00 CEST.
  • *Late-breaking abstracts available from October 11, 2023 at 8:00 CEST.
  • Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the Phase III OCARINA II study
    Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the Phase Ib dose-finding OCARINA I study
    The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies
    Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis
    October 13 (Scientific Session 20: Female health)
    Ocrelizumab dose selection for treatment of paediatric relapsing-remitting multiple sclerosis: preliminary pharmacokinetic, safety and efficacy results from the OPERETTA 1 study
    Pregnancy and infant outcomes in women receiving ocrelizumab for the treatment of multiple sclerosis: analysis of the largest available outcome database
    Combining measures from clinical assessments, imaging and fluid biomarkers at one year to predict MS progression at two years
    Low disability accumulation after 4-year ocrelizumab therapy in treatment-naive patients with early-stage relapsing-remitting multiple sclerosis; data from the Phase IIIb ENSEMBLE study
    Utility and implementation of a federated research infrastructure to assess lack disease stability as a real-world surrogate of PIRA, by combining MS clinical trial and real-world cohort data (the INTONATE MS consortium)
    Specific unmet medical needs in the care of patients with relapsing multiple sclerosis: final results from the PROFILE RMS study
    Ocrelizumab safety under real-world conditions: Contrasting investigator-reported safety with patient-reported safety in people with multiple sclerosis (CONFIDENCE, COMPASS and TrotzMS)
    Implications of progression independent of relapse activity (PIRA) for multiple sclerosis clinical trials: item banks could provide the precise patient-reported outcome measures needed
    Cerebrospinal fluid and MRI analyses of fenebrutinib treatment in multiple sclerosis reveal brain penetration and early reduction of new lesion activity: results from the Phase II FENopta study
    October 13 (Scientific Session 22: Late Breaking Abstracts*)
    Fenebrutinib, a noncovalent, reversible, Bruton's tyrosine kinase inhibitor, potently blocks neuroinflammation induced by Fcy receptor activation in human microglial systems: implications for multiple sclerosis treatment
    Long-term efficacy of satralizumab in patients with AQP4-IgG+ NMOSD: updated analysis from the open-label SAkuraMoon study
    Addressing the burdens of neuromyelitis optica spectrum disorder amid challenges of the COVID-19 pandemic: real-world perspectives from patients
    Satralizumab treatment in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder: a retrospective case series
    Relapse under the prescription of satralizumab in neuromyelitis optica spectrum disorder: analysis of a Japanese claims database
    Use of immunosuppressive therapy among patients with NMOSD using satralizumab treatment: a study based on Japanese real-world data

Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 5, 2023
AIM, PD, Event, NMOSD, Parkinson's disease, TSX, Neuromyelitis optica spectrum disorder, Immunosuppression, Conference

TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually.

Key Points: 
  • TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually.
  • Dr. Paulini will provide a corporate overview and will focus his presentation on the Company’s Autoimmunity Modifying (AIM) Biologicals development programs.
  • In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the conference, please visit the conference website .